RA
CLVS

Royce & Associates’s Clovis Oncology, Inc. CLVS Stock Holding History

Royce & Associates’s Portfolio CLVS Stock Details CLVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-50,000
Closed -$3.4M – 1294
2017
Q4 		$3.4M Hold
50,000
– – 0.02% 706
2017
Q3 		$4.12M Sell
50,000
-16,000
-24% -$1.27M 0.03% 635
2017
Q2 		$6.18M Sell
66,000
-10,000
-13% -$612K 0.04% 524
2017
Q1 		$4.84M Hold
76,000
– – 0.03% 585
2016
Q4 		$3.38M Buy
+76,000
New +$2.67M 0.02% 683

Other funds holding CLVS

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
BlackRock
BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return
PC
PointState Capital New York $4.31B AUM 42.31% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
O
OrbiMed New York $4.59B AUM 125.28% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CG
Carmignac Gestion Paris, France $6.51B AUM 19.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return